KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.

Rui You, Gui-Qiong Xu, Xi Ding, Jin-Hui Liang, Zhi-Gang Liu, Xiong Zou, You-Ping Liu, Guang-Yuan Hu, Yi-Min Liu, Chong-Yang Duan, Li-Zhi Liu, Wei-Jing Zhang, Qian Liu, Hui-Feng Li, Yan-Feng Ouyang, Xiao-Tong Duan, Qin Wang, Lan Peng, Jiong-Lin Liang, Zheng-Kai Feng, Zi-Han Qin, Xiao Liu, Zhi-Kun He, Bin Zhang, Guo-Xian Long, Yan-Hui Jiang, Feng Lei, Pei-Yu Huang, Yi-Jun Hua, Ming-Yuan Chen

BMJ 392 e085863

PMID41667193
PMCIDPMC12887725
DOI10.1136/bmj-2025-085863
发表日期2026-02-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

OBJECTIVE: To assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma. DESIGN: Multicentre, randomised, open label, phase 3 trial. SETTING: Seven hospitals in China between 18 August 2020 and 21 June 2022. PARTICIPANTS: Adults aged 18-70 years with newly diagnosed high risk nasopharyngeal carcinoma after three cycles of induction chemotherapy with gemcitabine and cisplatin (stage 4a, stage 2-3 with stable or progressive disease, or detectable Epstein-Barr virus DNA). INTERVENTIONS: Patients were randomly assigned (1:1) to receive combination chemoradiotherapy based on cisplatin (standard treatment group) or standard treatment with 19 cycles of intravenous camrelizumab (200 mg) once every three weeks (radiotherapy plus two concurrent cycles and 17 adjuvant cycles; camrelizumab group). MAIN OUTCOME MEASURES: The primary endpoint in the intention-to-treat group was progression-free survival, defined as the time from randomisation to disease recurrence (locoregional or distant) or death from any cause. Secondary endpoints included safety and overall survival. RESULTS: 390 patients were enrolled and randomly assigned to the camrelizumab group (n=194) or the standard treatment group (n=196). At median follow-up of 39.9 months (interquartile range 36.8-43.4 months), progression-free survival was higher in the camrelizumab group than the standard treatment group (36 months: 83.4%, 95% confidence interval 78.3% to 88.8% v 71.3%, 65.2% to 77.9%; stratified hazard ratio 0.51, 95% confidence interval 0.34 to 0.77, P=0.001). The incidence of acute and late adverse events (grade 3 or 4) was 50.5% and 3.2% in the camrelizumab group compared with 48.7% and 3.7% in the standard treatment group. Immunological adverse events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group. CONCLUSION: The addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04453826.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig 2

Fig 2 Kaplan-Meier survival analysis of intention-to-treat population at 36 months

Progression-free_survival

Progression-free survival

Fig 2 · Panel Progression-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Progression-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
Distant_metastasis-free_survival

Distant metastasis-free survival

Fig 2 · Panel Distant_metastasis-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Distant_metastasis-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Locoregional_recurrence-free_survival

Locoregional recurrence-free survival

Fig 2 · Panel Locoregional_recurrence-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Locoregional_recurrence-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Overall_survival

Overall survival

Fig 2 · Panel Overall_survival

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Overall_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 Flow chart showing patients and treatment groups
非 KM Figure